Garranzo Asensio, MaríaRodríguez Cobos, JavierSan Millán, CoralPoves, CarmenFernández Aceñero, María JesúsPastor Morate, DanielViñal, DavidMontero Calle, AnaSolís Fernández, GuillermoCeron, María ÁngelesGámez Chiachio, ManuelRodríguez Martín, NuriaGuzmán Aránguez, Ana IsabelBarderas Manchado, RodrigoDomínguez , Gemma2026-01-122026-01-122022-07-16Garranzo-Asensio M, Rodríguez-Cobos J, San Millán C, Poves C, Fernández-Aceñero MJ, Pastor-Morate D, Viñal D, Montero-Calle A, Solís-Fernández G, Ceron MÁ, Gámez-Chiachio M, Rodríguez N, Guzmán-Aránguez A, Barderas R, Domínguez G. In-depth proteomics characterization of ∆Np73 effectors identifies key proteins with diagnostic potential implicated in lymphangiogenesis, vasculogenesis and metastasis in colorectal cancer. Mol Oncol. 2022 Jul;16(14):2672-2692. doi: 10.1002/1878-0261.13228. Epub 2022 Jun 7. PMID: 35586989; PMCID: PMC9298678.10.1002/1878-0261.13228https://hdl.handle.net/20.500.14352/129894Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related death worldwide. Alterations in proteins of the p53-family are a common event in CRC. ΔNp73, a p53-family member, shows oncogenic properties and its effectors are largely unknown. We performed an in-depth proteomics characterization of transcriptional control by ∆Np73 of the secretome of human colon cancer cells and validated its clinical potential. The secretome was analyzed using high-density antibody microarrays and stable isotopic metabolic labeling. Validation was performed by semiquantitative PCR, ELISA, dot-blot and western blot analysis. Evaluation of selected effectors was carried out using 60 plasma samples from CRC patients, individuals carrying premalignant colorectal lesions and colonoscopy-negative controls. In total, 51 dysregulated proteins were observed showing at least 1.5-foldchange in expression. We found an important association between the overexpression of ∆Np73 and effectors related to lymphangiogenesis, vasculogenesis and metastasis, such as brain-derived neurotrophic factor (BDNF) and the putative aminoacyl tRNA synthase complex-interacting multifunctional protein 1 (EMAP-II)-vascular endothelial growth factor C-vascular endothelial growth factor receptor 3 axis. We further demonstrated the usefulness of BDNF as a potential CRC biomarker able to discriminate between CRC patients and premalignant individuals from controls with high sensitivity and specificity.engAttribution-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-sa/4.0/journal articlehttps://doi.org/10.1002/1878-0261.1322835586989open access616-006.04Colorectal cancerIn-depth proteomicsLymphangiogenesisSecretomeΔNp73 effectorsBioquímica (Medicina)Oncología3201.01 Oncología